Early prediction of formulation behaviour for new antibody products
Early prediction of formulation behaviour for new antibody products
批准号:
2367694
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2019
资助国家:
英国
项目状态:
已结题
起止时间:
2019 至 --
中文摘要
基于抗体的生物制剂,如单克隆抗体(mab),由于其独特的治疗潜力,是生物制药行业快速增长的一部分。到2022年,全球基于抗体的治疗药物市场预计将达到1146亿美元,从2017年到2022年的复合年增长率(CAGR)为6.3% (Dewan, 2017)。与传统的小分子药物相比,单克隆抗体具有高水平的特异性和低毒性,这使得它们能够成功地靶向以前无法治疗的适应症(Keizer等,2010)。因此,开发新型单克隆抗体疗法和生物仿制药的研究兴趣有所上升。配方开发仍然是单克隆抗体生产的主要挑战,因为对经济有效地配制治疗药物以安全交付给患者的要求很高。这些大分子的复杂性增加使它们更加不稳定,容易发生化学和/或物理降解,因此需要特殊的处理和储存。冻干或冷冻干燥是工业中常用的一种方法,用于保存单克隆抗体的化学和生物特性,以保持长期稳定性并延长保质期(Carpenter等人,2002年)。蛋白质聚集是一个常见的问题,可以发生在生产过程的任何阶段,直到给药。聚集不仅会影响蛋白质功能,降低产物产量,还会缩短治疗半衰期,引起患者的免疫原性反应(Wang et al, 2007)。SPEL之前的工作已经揭示了从自相互作用色谱(SIC)获得的渗透第二病毒系数(B22)与单抗聚集倾向之间的关系(Hedberg等人,2018)。该项目的目的是进一步研究液体和冻干生物治疗药物的聚集倾向,并了解聚集机制,以帮助预测新型单克隆抗体的聚集倾向。除了广泛的结构表征外,还将研究功能以评估生物活性和免疫原性。
英文摘要
Antibody-based biologics such as monoclonal antibodies (mAbs) are a fast-growing segment of the biopharmaceutical industry due to their distinctive therapeutic potential. The global market for antibody-based therapeutics is forecasted to reach $114.6 billion by 2022 growing at a compound annual growth rate (CAGR) of 6.3% from 2017 to 2022 (Dewan, 2017). In contrast to traditional small molecule drugs, mAbs have high levels of specificity with low toxicity profiles, which drives their success in targeting previously untreatable indications (Keizer et al, 2010). Consequently, there has been a rise in research interest in developing novel mAb therapies and biosimilars.Formulation development remains a major challenge in mAb production as there is a high demand to formulate therapeutics economically and effectively for safe delivery to patients. The increased complexity of these large molecule makes them more unstable and prone to chemical and/or physical degradation, therefore requiring special handling and storage. Lyophilisation, or freeze drying is a common method used in industry to preserve chemical and biological properties of mAbs to sustain long-term stability and improve shelf life (Carpenter et al, 2002). Protein aggregation is a common problem that can occur at any stage of the manufacturing process up until drug administration. Not only can aggregation affect protein function and decrease product yield, it can also reduce the therapeutic half-life and cause immunogenic reactions in patients (Wang et al, 2007).Previous work at SPEL have uncovered the relationship between the Osmotic second virial coefficient (B22) obtained from self-interaction chromatography (SIC) and propensity of mAb aggregation (Hedberg et al, 2018). The aim of the project is to further investigate aggregation propensity of liquid and lyophilised biotherapeutics and understand the mechanisms of aggregation to help predict aggregation tendencies of novel mAbs. In addition to extensive structural characterisation, functionality will be investigated to assess biological activity and immunogenicity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
基于深穿透拉曼光谱的安全光照剂量的深层病灶无创检测与深度预测
-
批准号:82372016
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:林俐
-
依托单位:
高性能纤维混凝土构件抗爆的强度预测
-
批准号:51708391
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2017
-
负责人:李杰
-
依托单位:
隧道超前探测的三分量光纤地震加速度检波机理与应用研究
-
批准号:51079080
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2010
-
负责人:蒋奇
-
依托单位:
非编码RNA与蛋白质相互作用预测算法的研究
-
批准号:31000586
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2010
-
负责人:刘长宁
-
依托单位: